Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. reports developments for a global healthcare company with a portfolio spanning generics, established brands and innovative medicines. News commonly covers quarterly results, guidance, cash deployment, dividends, capital allocation and management changes, alongside product launches and pipeline updates across major therapeutic areas.
Company updates also include scientific presentations and regulatory actions tied to specific medicines and candidates, including Effexor in Japan, ophthalmology programs such as phentolamine ophthalmic solution and RYZUMVI, and an investigational low-dose estrogen combined hormonal contraceptive weekly patch. Viatris was formed through the combination of Mylan and Pfizer's Upjohn business and operates with global centers in the U.S., China and India.
Viatris (Nasdaq: VTRS) announced that the U.S. FDA has accepted its New Drug Application for MR-107A-02 fast-acting meloxicam, a non-opioid treatment for moderate-to-severe acute pain. The FDA set a PDUFA goal date of Dec. 27, 2026.
The NDA is backed by two Phase 3 randomized, double-blind, placebo- and active-controlled trials in herniorrhaphy and bunionectomy patients. Fast-acting meloxicam met primary and secondary endpoints, reduced opioid use, and showed a safety profile consistent with its mechanism of action.
Viatris (Nasdaq: VTRS) will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026 at 8:00 a.m. PT / 11:00 a.m. ET. A live webcast will be available at investor.viatris.com, with an archived version accessible there for a limited time.
Viatris (Nasdaq: VTRS) reported Q1 2026 total revenues of $3.52B, up 8% reported and 3% operationally; U.S. GAAP net earnings were $176M and Adjusted EBITDA was $1.05B. The company reaffirmed 2026 guidance, including $14.45–$14.95B revenue and $4.15–$4.45B adjusted EBITDA, and expects >$2.5B cash available for deployment in 2026.
Key regional strength was Greater China; operational headwinds included ARV supply constraints in Emerging Markets. Cash from operations and free cash flow were lower versus Q1 2025.
Viatris (Nasdaq: VTRS) announced a quarterly dividend of $0.12 per share, declared May 4, 2026. The dividend is payable on June 17, 2026 to shareholders of record at the close of business on May 22, 2026.
Viatris (Nasdaq: VTRS) announced that Chief Financial Officer Theodora "Doretta" Mistras will depart for a new professional opportunity; she will remain through May 22, 2026.
Paul Campbell, Chief Accounting Officer and Corporate Controller, is named interim CFO effective May 8, 2026 while a permanent successor search is conducted. Viatris will report Q1 2026 results on May 7, 2026 and host an 8:30 a.m. ET conference call.
Viatris (Nasdaq: VTRS) announced six abstracts on its investigational low-dose estrogen combined hormonal contraceptive (MR-100A-01) will be presented at the ACOG 2026 Annual Clinical & Scientific Meeting in Washington, D.C., May 1–3, 2026. Presentations include positive Phase 3 efficacy and safety results, adhesion and pharmacokinetic data, and cycle control findings. Sessions and times for six electronic poster presentations and an educational symposium supported by Viatris are listed; Viatris will be at booth #223.
Viatris (Nasdaq: VTRS) will report first quarter 2026 financial results on Thursday, May 7, 2026. Company executives will host a live webcast at 8:30 a.m. ET the same day to discuss results.
Investors can access the live webcast at investor.viatris.com, call 844.308.3344 (domestic) or 412.317.1896 (international). A replay will be available on the company website after the call.
Viatris (Nasdaq: VTRS) will present four abstracts at the ASCRS Annual Meeting in Washington, D.C., April 10–13, 2026, covering ophthalmology data including full VEGA-3 Phase 3 results for MR-141, a Phase 1 varenicline nasal spray study in Japanese adults, and analyses of RYZUMVI and MR-142.
Presentations include oral and electronic posters; Viatris also provided an independent educational grant for a symposium on April 11, 6:00–7:30 p.m. ET, and will staff booth #233.
Viatris (Nasdaq: VTRS) announced MHLW approval of Effexor SR 37.5 mg / 75 mg for adults with generalized anxiety disorder (GAD) in Japan on March 23, 2026.
This makes Effexor the first and only approved GAD treatment in Japan; approval is supported by a Phase 3 trial (p=0.012) and long-term extension data.
Viatris (Nasdaq: VTRS) outlined a strategic plan and financial framework aimed at delivering sustained revenue and earnings growth through 2030. Key numerical targets include 5%-6% total revenues CAGR, 7%-8% adjusted EBITDA CAGR, 9%-10% adjusted EPS CAGR and > $3.0B free cash flow in 2030.
The company expects > $11 billion in cash available for deployment through 2030, identified ≈ $650 million gross cost savings, and highlighted near-term launches and pipeline assets (selatogrel, cenerimod) as potential upside drivers.